Tests HD-6277 doses against placebo in adults with type 2 diabetes
Tests HD-6277 doses against placebo in adults with type 2 diabetes.
Key facts
- Who runs it
- Hyundai Pharm
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 160 people, planned
- Started
- 12 Dec 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- HD-6277 100mg
- HD-6277 50mg
- HD-6277 25mg
- Placebo
- Record updated
- 13 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone.
- Age
- 19 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes (T2DM) with HbA1c between 7.0% (53 mmol/mol) and 10.0% (86 mmol/mol) (inclusive).
- Earlier treatment
- Must have used diet and exercise alone for at least 8 weeks before screening.
- Biomarker or test result
- HbA1c between 7.0% (53 mmol/mol) and 10.0% (86 mmol/mol) (inclusive).
Main reasons for not taking part
- Type 1 diabetes or another immune-mediated diabetes syndrome
- BMI above 40 kg/m2
- C-peptide below 0.5ng/mL
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening
Who cannot take part
- Type 1 diabetes or another immune-mediated diabetes syndrome
- BMI: > 40 kg/m2
- C-peptide: < 0.5ng/mL
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 75 years old?
Where in South Korea
- Korea University Anam HospitalSeoul, South KoreaContact: Sin-Gon Kim, PhDTaking people
About the trial
What the trial wants to find out
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
The 4 groups in the trial
- HD-6277 100mg tabTreatment being tested
Oral tablet
Treatment: HD-6277 100mg
- HD-6277 50mg tabTreatment being tested
Oral tablet
Treatment: HD-6277 50mg
- HD-6277 25mg tabTreatment being tested
Oral tablet
Treatment: HD-6277 25mg
- PlaceboPlacebo, for comparison
Oral tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Plain-language title
- Tests HD-6277 doses against placebo in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06647550, who can take part
- Record updated
- 13 December 2024